OncLive TV

Sanjeet Singh Dadwal, MD, discusses the investigation of posoleucel as a prevention strategy for infections in patients following an allogenic hematopoietic cell transplant.

Johannes Zakrzewski, MD, discusses the investigation of a nanoframework-based delivery system for IT848 in hematologic malignancies.

Claire F. Verschraegen, MD, discusses the need for predictive biomarkers for the use of immunotherapy in the treatment of melanoma.

Jane L. Meisel, MD, discusses the effect of the HER2-low classification for patients with breast cancer.

Tanya Dorff, MD, discusses remaining questions regarding sequencing in metastatic renal cell carcinoma.

Craig Sauter, MD, discusses important considerations regarding the use of pembrolizumab after autologous stem cell transplant in T-cell non-Hodgkin lymphoma.

Vamsidhar Velcheti, MD, discusses the evaluation of immunotherapy combination regimens for patients with metastatic non–small cell lung cancer.

Al-Ola A. Abdallah, MD, discusses interim results from an ongoing phase 1 trial of HPN217 in heavily pretreated patients with relapsed/refractory multiple myeloma.

Carmelo Carlo-Stella, MD, PhD, discusses updated results from a phase 1 dose-escalation study of subcutaneous and intravenous RG6234 in relapsed/refractory multiple myeloma.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss second-line treatment options for patients with non—small cell lung cancer who progressed on first-line EGFR-directed tyrosine kinase inhibitors.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the evaluation of CEACAM5 biomarker testing in non–small cell lung cancer.

Balazs Halmos, MD, Martin F. Dietrich, MD, PhD, Roy S. Herbst, MD, PhD, Suresh S. Ramalingam, MD, FACP, FASCO, Mark Socinski, MD, and Heather Wakelee, MD, FASCO, discuss the use of antibody-drug conjugates (ADCs) in HER2-mutated non–small cell lung cancer.

Paolo Tarantino, MD, discusses the impact of the phase 3 DESTINY-Breast04 trial in the treatment of HER2-low breast cancer.

Elias Jabbour, MD, discusses the evaluation of olverembatinib in patients with ponatinib-resistant chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.

Michelle Shiller, DO, AP/CP, MGP, discusses the role of trastuzumab deruxtecan in patients with HER2-positive breast cancer.

Shaji Kumar, MD, discusses the updated data from the phase 3 MAIA trial in newly diagnosed multiple myeloma.

Stephen T. Oh, MD, PhD, discusses the anemia benefit of pacritinib in patients with myelofibrosis.

Gopa Iyer, MD, discusses the unmet needs for patients with solid tumors harboring TSC1/2 mutations.

Paul J. Shaughnessy, MD, discusses the potential of the phase 1/2 FELIX trial to address unmet needs in relapsed/refractory B-cell acute lymphoblastic leukemia.

Lubna N. Chaudhary, MD, discusses the correlation between PD-L2 status and progression-free survival rates in treatment-naïve estrogen receptor–positive breast cancer.

Vijayakrishna Gadi, MD, PhD, discusses the investigation of AMUN-003 in triple-negative breast cancer.

Aditya Bardia, MD, MPH, discusses the investigation of oral selective estrogen receptor degraders in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer.

Virginia G. Kaklamani, MD, discusses the evolution of oral selective estrogen receptor degraders in estrogen receptor-positive breast cancer.

Raajit K. Rampal, MD, PhD, discusses the importance of clinical trial enrollment in patients with myelofibrosis.

Stephen T. Oh, MD, PhD, discusses the benefits of pacritinib in patients with myelofibrosis.

Jeanne M. Palmer, MD, discusses total symptom scores in patients with myelofibrosis with thrombocytopenia.

John M. Burke, MD, discusses the underrepresentation of elderly patients in clinical trials for lymphoma.

Carsten Niemann, MD, PhD, discusses ibrutinib plus venetoclax vs chlorambucil and obinutuzumab in mutated chronic lymphocytic leukemia.

David L. Saltman, MD, PhD, discusses the use of the 27-gene Determa immuno-oncology assay to inform use of single-agent immunotherapy in patients with advanced-stage non–small cell lung cancer.

Craig Sauter, MD, discusses the investigation of pembrolizumab given after stem cell transplant in T-cell non-Hodgkin lymphoma.